Lipoxen PLC
13 July 2006

                                  Lipoxen PLC
                          ("Lipoxen" or "the Company")


        Lipoxen Receives UK Biotechnology Entrepreneur of the Year Award


London, UK, 13 July, 2006 - Lipoxen PLC (AIM: LPX), a biopharmaceutical company
specialising in the development of high value differentiated biologicals,
vaccines and oncology drugs, is very pleased to announce that it has received
the UK Trade & Investment Special Award 2006. The award, which was presented
yesterday in a ceremony at the Foreign and Commonwealth Office in London, is in
recognition of Lipoxen's product development efforts in India in partnership
with local business, namely the Serum Institute of India, one of the world's
leading vaccine companies.

The award received by Lipoxen is one of several presented yesterday by UK Trade
& Investment in association with London First as part of the 2006 UK
Biotechnology Entrepreneur of the Year Awards. These awards are designed to
recognise the achievements of the UK's growing biotechnology sector and are
voted on by a panel of leading biotechnology industry figures, including Simon
Best, Chairman of the UK BioIndustry Association and Sir William Castell, Chair
of the Wellcome Trust.

Winners of the awards will be profiled in UK Trade & Investment's signature
publication for the Biotech Sector "UK Strengths in Biotech". The document,
which will be distributed across the globe, details UK capability and highlights
the sector's successes and opportunities to potential international business
partners.

Peter Laing, MD of Lipoxen Technologies Ltd commented: "I am very pleased to
accept this award on behalf of Lipoxen. It recognizes the great potential of our
proprietary technology combined with the manufacturing power of Serum Institute
to create new products that will be competitive on a global scale. We are very
pleased to have worked with the UKTI to bring this collaboration about. The
award is a formidable tribute to the hard work and inspiration of the company
and its employees."


Enquiries


Lipoxen PLC
Peter Laing, MD of Lipoxen Technologies Ltd                   +44 (0)7990 523798

Citigate Dewe Rogerson                                       +44 (0)20 7638 9571
David Dible/Yvonne Alexander


Notes to Editor


Lipoxen PLC (LSE:LPX) is a biopharmaceutical company specialising in the
development of high value differentiated biologicals, vaccines and oncology
drugs. Potential products, which address markets in excess of US$1 billion,
currently under development include improved formulations of important
biologicals including EPO, G-CSF, insulin and Interferon-alpha based on
Lipoxen's proprietary PolyXen(R) technology. This technology is designed to
improve the stability, biological half-life and immunologic characteristics of
therapeutic proteins naturally. Lipoxen has two further naturally-derived
proprietary delivery technologies ImuXen(R) and a related liposomal technology
for the formulation of cytotoxic oncology drugs, which are being developed to
enhance the efficacy and safety of various vaccines such as Hepatitis B and
pneumococcal vaccines, as well as a number of anti-cancer agents like
paclitaxel. The Company's proprietary delivery technologies are attracting
significant interest and Lipoxen is already co-developing products with Serum
Institute of India, one of the world's leading vaccine companies. In addition,
its technologies are being currently evaluated by leading biotechnology
companies such as Baxter, Amgen, Genzyme and Genentech.

Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange
in January 2006.

About UK Trade & Investment

UK Trade & Investment is the lead government organisation that provides support
for UK companies looking to develop international business and for overseas
companies wishing to invest in the UK. UK Trade & Investment has a wide range of
services, backed-up by a network of trade advisors worldwide who can provide
market intelligence, advice on regulations, sales leads, and financial and
practical support. www.uktradeinvest.gov.uk

About London First

London First is a business membership group whose aim is to improve and promote
London with the objective of ensuring that London maintains and enhances its
position as a leading world city. We do this by mobilising the experience,
expertise and enthusiasm of the private sector to develop practical solutions to
the challenges facing London and to lobby central and London government for the
investment that London needs in its infrastructure.

London First delivers its activities with the support of 300 of the capital's
major businesses in key sectors such as finance, professional services,
property, ICT, creative industries, hospitality and retail. Membership also
includes all of London's higher education institutions as well as further
education colleges and NHS hospital trusts. Our members represent a quarter of
London's GDP.

www.london-first.co.uk


This announcement includes 'forward-looking statements' which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Company's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Company's products and services), and any
statements preceded by, followed by or that include forward-looking terminology
such as the words 'targets', 'believes', 'estimates', 'expects', 'aims',
'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or
similar expressions or the negative thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors
beyond the Company's control that could cause the actual results, performance or
achievements of the Company to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Company's present and future business strategies and the
environment in which the Company will operate in the future. Among the important
factors that could cause the Company's actual results, performance or
achievements to differ materially from those in forward-looking statements
include those relating to The Company's funding requirements, regulatory
approvals, clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements speak only as
at the date of this announcement. The Company expressly disclaims any obligation
or undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement  to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking statement.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAAKNKKDBKDBOD